| Biotechnology Industry | Healthcare Sector | - CEO | NZX Exchange | NZBLTE0002S8 ISIN |
| New Zealand Country | 39 Employees | - Last Dividend | 13 Nov 2007 Last Split | - IPO Date |
BLIS Technologies Limited is an innovative company engaged in the development and sale of healthcare products that leverage the power of beneficial bacteria with bacteriocin activity. Focusing on the creation of probiotic formulations, BLIS Technologies targets a variety of health concerns, emphasizing oral and dental health, ear, nose, and throat well-being, and the skin's microbiome. Since its foundation in 2000, the company has expanded its market reach beyond its home base in Dunedin, New Zealand, to include regions such as the Asia Pacific, Europe, the Middle East, Africa, and North America. This global presence underlines its commitment to providing health solutions that are both advanced and accessible worldwide.
BLIS K12
A probiotic supplement designed specifically to support the ear, nose, and throat health of young children. BLIS K12 is also known for its benefits in improving immunity against common infections and in managing bad breath. This strain of bacteria acts as a protective guard, promoting a healthy balance of microflora in children's sensitive ENT areas.
BLIS M18
Developed to maintain and enhance dental health, BLIS M18 is an oral probiotic that supports the health of teeth and gums. Its targeted action helps in the prevention of dental plaque formation, gum disease, and carries a promise of a healthier mouth, contributing to overall dental and oral hygiene and well-being.
BLIS Q24
This probiotic supplement is aimed at caring for the skin by balancing and restoring the skin microbiome. By promoting a healthy bacterial balance on the skin, BLIS Q24 helps in restoring skin health, clarity, and radiance, offering a natural solution for those looking to improve their skin’s appearance and resilience against external factors.